Oppenheimer Reiterates Outperform on Viridian Therapeutics, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has reiterated an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) but has lowered the price target from $31 to $28.
August 12, 2024 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer has reiterated an Outperform rating on Viridian Therapeutics but lowered the price target from $31 to $28.
The reiteration of the Outperform rating is positive, but the lowered price target may temper investor enthusiasm. The overall impact is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100